eResearchTechnology, Inc. Signs a $3 Million Contract to Supply US Oncology, Inc. With its Integrated Suite of Software and Services For Speeding Drug Development in Clinical Research

eRT Further Penetrates the Oncology Arena Offering Its eResearch Network And

Community Technology to the Nation's Most Extensive Oncology Network



Apr 30, 2001, 01:00 ET from eResearchTechnology, Inc.

    PHILADELPHIA, April 30 /PRNewswire/ --
     eResearchTechnology, Inc. (eRT),  (Nasdaq:   ERES), a leading e-research
 technology and services provider announced today a three year, $3 Million
 contract with US Oncology, Inc. (Nasdaq:   USON), to acquire eRT's electronic
 research network (eResNet(TM)) and community (eResCom(TM)) technology along
 with a full complement of application service provider (ASP) services to
 ensure its rapid deployment.
     "The eResNet technology will allow US Oncology to build an integrated
 electronic research network that accelerates the collection, processing, and
 presentation of their clients' clinical data that is obtained from their
 network of community-based cancer physicians, patients, clinicians, nurses,
 and administrators," stated Joseph Esposito, President and CEO of eRT.
     "eRT's technology will enable US Oncology to leverage our scientific
 capabilities and physician network to pursue our growth strategies in
 research, drug development, bio-informatics, and new diagnostic services,"
 said Atul Dhir, M.D., D.Phil., President of the Cancer Information and
 Research Group.  "We can now harvest the data and therapeutic knowledge
 accumulated as a result of supplying care for 15% of newly diagnosed cancer
 patients in the US, utilizing 72 comprehensive cancer centers across the
 country to provide better outcomes for our patients and our clients."
     "We selected eResearchTechnology because they offer an integrated
 electronic solution for managing clinical research studies," noted Terry
 Murdock, Vice President of US Oncology Research.  "As we continue to expand
 and improve the operations of our oncology network's integrated research
 platform, eResNet(TM) and eResCom(TM) will provide US Oncology Research a
 solid foundation for accelerating clinical drug development and for producing
 quality data in a validated environment."
     US Oncology, Inc. represents the nation's most extensive oncology network,
 including cancer research, diagnostic and radiation centers, outpatient blood
 and marrow stem cell transplant, and pharmaceutical management services. The
 research group, within US Oncology, offers an integrated platform for
 conducting Phase I through Phase IV clinical trials for new and approved
 cancer therapies through US Oncology's community-based physician practices and
 cancer centers. The US Oncology network operates in 27 states with over 865
 affiliated physicians in 496 medical office locations, including 72 integrated
 cancer centers.
     Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com),
 is a business-to-business provider of integrated software applications and
 technology consulting services to the pharmaceutical, biotechnology and
 medical device industries.  The Company offers Internet and other technology-
 based solutions designed to streamline the clinical trials process by enabling
 its customers to automate many parts of a clinical trial.  The Company is also
 a market leader in providing centralized core-diagnostic electrocardiographic
 services in a global basis.
 
     Statements included in this release may constitute forward-looking
 statements within the meaning of the Private Securities Litigation Reform Act
 of 1995.  Such statements involve a number of risks and uncertainties such as
 competitive factors, technological development, market demand, and the
 Company's ability to obtain new contracts and accurately estimate net revenues
 due to variability in size, scope and duration of projects, and internal
 issues in the sponsoring client.  Further information on potential factors
 that could affect the Company's financial results can be found in the
 Company's Report on Form 10-K filed with the Securities and Exchange
 Commission (SEC).
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X80353791
 
 

SOURCE eResearchTechnology, Inc.
    PHILADELPHIA, April 30 /PRNewswire/ --
     eResearchTechnology, Inc. (eRT),  (Nasdaq:   ERES), a leading e-research
 technology and services provider announced today a three year, $3 Million
 contract with US Oncology, Inc. (Nasdaq:   USON), to acquire eRT's electronic
 research network (eResNet(TM)) and community (eResCom(TM)) technology along
 with a full complement of application service provider (ASP) services to
 ensure its rapid deployment.
     "The eResNet technology will allow US Oncology to build an integrated
 electronic research network that accelerates the collection, processing, and
 presentation of their clients' clinical data that is obtained from their
 network of community-based cancer physicians, patients, clinicians, nurses,
 and administrators," stated Joseph Esposito, President and CEO of eRT.
     "eRT's technology will enable US Oncology to leverage our scientific
 capabilities and physician network to pursue our growth strategies in
 research, drug development, bio-informatics, and new diagnostic services,"
 said Atul Dhir, M.D., D.Phil., President of the Cancer Information and
 Research Group.  "We can now harvest the data and therapeutic knowledge
 accumulated as a result of supplying care for 15% of newly diagnosed cancer
 patients in the US, utilizing 72 comprehensive cancer centers across the
 country to provide better outcomes for our patients and our clients."
     "We selected eResearchTechnology because they offer an integrated
 electronic solution for managing clinical research studies," noted Terry
 Murdock, Vice President of US Oncology Research.  "As we continue to expand
 and improve the operations of our oncology network's integrated research
 platform, eResNet(TM) and eResCom(TM) will provide US Oncology Research a
 solid foundation for accelerating clinical drug development and for producing
 quality data in a validated environment."
     US Oncology, Inc. represents the nation's most extensive oncology network,
 including cancer research, diagnostic and radiation centers, outpatient blood
 and marrow stem cell transplant, and pharmaceutical management services. The
 research group, within US Oncology, offers an integrated platform for
 conducting Phase I through Phase IV clinical trials for new and approved
 cancer therapies through US Oncology's community-based physician practices and
 cancer centers. The US Oncology network operates in 27 states with over 865
 affiliated physicians in 496 medical office locations, including 72 integrated
 cancer centers.
     Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com),
 is a business-to-business provider of integrated software applications and
 technology consulting services to the pharmaceutical, biotechnology and
 medical device industries.  The Company offers Internet and other technology-
 based solutions designed to streamline the clinical trials process by enabling
 its customers to automate many parts of a clinical trial.  The Company is also
 a market leader in providing centralized core-diagnostic electrocardiographic
 services in a global basis.
 
     Statements included in this release may constitute forward-looking
 statements within the meaning of the Private Securities Litigation Reform Act
 of 1995.  Such statements involve a number of risks and uncertainties such as
 competitive factors, technological development, market demand, and the
 Company's ability to obtain new contracts and accurately estimate net revenues
 due to variability in size, scope and duration of projects, and internal
 issues in the sponsoring client.  Further information on potential factors
 that could affect the Company's financial results can be found in the
 Company's Report on Form 10-K filed with the Securities and Exchange
 Commission (SEC).
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X80353791
 
 SOURCE  eResearchTechnology, Inc.